The global PARP Inhibitor Market is estimated to be valued at US$ 887.7 million in 2018 and is expected to exhibit a CAGR of 32.4% over the forecast period, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview:

PARP inhibitors are a class of drugs that inhibit the enzyme poly ADP ribose polymerase (PARP), which plays a crucial role in DNA repair. These inhibitors are primarily used in the treatment of various cancers, including ... Read more

Poly (ADP-ribose) polymerase (PARP) inhibitors are novel class of drugs developed to treat BRCA gene related cancers. It works by blocking the action of PARP enzyme that helps DNA repair mechanism. Without this repair DNA damage accumulates in cancer cells leading to their death. The global PARP Inhibitor Market is estimated to be valued at US$ 6.13 Bn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, ... Read more